99 related articles for article (PubMed ID: 15217132)
1. [Diagnosis and management of advanced hormone-refractory prostate cancer: results of a practice survey on 301 French urologists].
Colombel M; Davin JL; Filleul A; Rousseau C
Prog Urol; 2004 Apr; 14(2):182-8. PubMed ID: 15217132
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of non-muscle invasive bladder tumours by instillations of mitomycin C and BCG: a survey on French urologists by the French Urological Association].
Descazeaud A; Mignard JP; Davin JL; Irani J
Prog Urol; 2009 Oct; 19(9):624-31. PubMed ID: 19800553
[TBL] [Abstract][Full Text] [Related]
3. [Observational survey of the French Urological Association evaluating intermittent hormonal modalities treatment in prostate cancer in France].
Salomon L; Ploussard G; Coloby P; Kouri G; Lebret T; Méjean A; Prunet D; Soulié M
Prog Urol; 2014 May; 24(6):367-73. PubMed ID: 24821560
[TBL] [Abstract][Full Text] [Related]
4. What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer?
Descazeaud A; Rubin MA; Allory Y; Burchardt M; Salomon L; Chopin D; Abbou C; de la Taille A
Eur Urol; 2005 Dec; 48(6):911-5. PubMed ID: 16140457
[TBL] [Abstract][Full Text] [Related]
5. Current status and prospects of androgen depletion therapy for prostate cancer.
Akaza H
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
[TBL] [Abstract][Full Text] [Related]
6. Practice trends in the diagnosis and management of prostate cancer in the United States.
Gee WF; Holtgrewe HL; Albertsen PC; Litwin MS; Manyak MJ; O'Leary MP; Painter MR
J Urol; 1995 Jul; 154(1):207-8. PubMed ID: 7539862
[TBL] [Abstract][Full Text] [Related]
7. Therapies used in prostate cancer patients by European urologists: data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates.
Heidenreich A; Witjes WP; Bjerklund-Johansen TE; Patel A;
Urol Int; 2012; 89(1):30-8. PubMed ID: 22699678
[TBL] [Abstract][Full Text] [Related]
8. Assessment of American urologists' approach to hormonal management of prostate cancer.
Warren KS; Osborn J; Chodak GW
Urology; 2006 Dec; 68(6):1305-7. PubMed ID: 17169651
[TBL] [Abstract][Full Text] [Related]
9. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
10. [French urologist's opinion on testosterone deficiency syndrome: Afu's andrology committee survey].
Tostain J; Coeuret C;
Prog Urol; 2008 Oct; 18(9):601-7. PubMed ID: 18986633
[TBL] [Abstract][Full Text] [Related]
11. Roles of the urologist and nurse from the perspective of patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue therapy.
Lebret T; Bouregba A
BJU Int; 2008 Nov; 102(10):1419-24. PubMed ID: 18549431
[TBL] [Abstract][Full Text] [Related]
12. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
13. [Current place of chemotherapy in the treatment of hormone-refractory metastatic prostate cancer].
Breton X; Lechevallier E; Coulange C
Prog Urol; 2005 Jun; 15(3):398-404. PubMed ID: 16097142
[TBL] [Abstract][Full Text] [Related]
14. Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists.
Penson D; Moul J; Gandhi S; Newling D
Urology; 2006 Jul; 68(1):80-4. PubMed ID: 16777198
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
Miyake H; Hara I; Yamazaki H; Eto H
Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
[TBL] [Abstract][Full Text] [Related]
16. [Role of hormonotherapy in the treatment of metastatic prostate cancer].
Lebret T; Méjean A
Prog Urol; 2008 Nov; 18 Suppl 7():S332-7. PubMed ID: 19070812
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
18. The trend of managing prostate cancer in Taiwan.
Wong WY; Chen SC; Chueh SC; Chen J
Int J Urol; 2004 Jul; 11(7):510-4. PubMed ID: 15242360
[TBL] [Abstract][Full Text] [Related]
19. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
El Demery M; Pouessel D; Avancès C; Iborra F; Rebillard X; Faix A; Ségui B; Delbos O; Ayuso D; Culine S
Prog Urol; 2006 Jun; 16(3):320-3. PubMed ID: 16821344
[TBL] [Abstract][Full Text] [Related]
20. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
